Citadel Advisors’s Elevation Oncology ELEV Stock Holding History

Citadel Advisors’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,000	Closed	-$1.04K	–	13153
2025 Q1	$1.04K	Buy	4,000 +700	+21%	+$400	﹤0.01%	14178
2024 Q4	$1.86K	Sell	3,300 -24,300	-88%	-$14.3K	﹤0.01%	14140
2024 Q3	$16.6K	Buy	27,600 +25,500	+1,214%	+$37.8K	﹤0.01%	12924
2024 Q2	$5.67K	Buy	+2,100	New	+$7.91K	﹤0.01%	13379

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's ELEV Position: Q3 2025 in Review

Citadel Advisors sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 355,203 shares — an estimated $130K sold.

Citadel Advisors first reported a position in ELEV in Q4 2021 and held it in 8 quarters. The position peaked at $8.05M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Citadel Advisors reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 355,203 Elevation Oncology shares in Q3 2025, an estimated $130K.
Citadel Advisors first reported a position in Elevation Oncology in Q4 2021 and held it in 8 quarters.
Citadel Advisors's Elevation Oncology position peaked at $8.05M in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.